Citadel Advisors’s Alexza Pharmaceuticals Inc ALXA Stock Holding History

Citadel Advisors’s Portfolio ALXA Stock Details ALXA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-28,600	Closed	-$14K	–	7881
2016 Q1	$14K	Buy	+28,600	New	+$12.5K	﹤0.01%	6563
2015 Q2	–	Sell	-3,200	Closed	-$7K	–	9363
2015 Q1	$7K	Sell	3,200 -10,800	-77%	-$22.2K	﹤0.01%	8279
2014 Q4	$21K	Buy	14,000 +4,600	+49%	+$8.21K	﹤0.01%	7776
2014 Q3	$22K	Buy	9,400 +2,300	+32%	+$8.78K	﹤0.01%	7378
2014 Q2	$32K	Hold	7,100	–	–	﹤0.01%	7051
2014 Q1	$31K	Sell	7,100 -9,500	-57%	-$48.7K	﹤0.01%	7079
2013 Q4	$79K	Sell	16,600 -20,400	-55%	-$100K	﹤0.01%	5782
2013 Q3	$189K	Sell	37,000 -2,100	-5%	-$9.88K	﹤0.01%	4822
2013 Q2	$170K	Buy	+39,100	New	+$177K	﹤0.01%	4807

Citadel Advisors's ALXA Position: Q2 2016 in Review

Citadel Advisors sold out of Alexza Pharmaceuticals Inc (ALXA) in Q2 2016, closing a stake of 21,244 shares — an estimated $10K sold.

Citadel Advisors first reported a position in ALXA in Q2 2013 and held it in 8 quarters. The position peaked at $61K in Q3 2014. 0 funds tracked by Wall St. Rank hold ALXA as of Q2 2016.

Citadel Advisors reported no remaining Alexza Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
Citadel Advisors sold 21,244 Alexza Pharmaceuticals Inc shares in Q2 2016, an estimated $10K.
Citadel Advisors first reported a position in Alexza Pharmaceuticals Inc in Q2 2013 and held it in 8 quarters.
Citadel Advisors's Alexza Pharmaceuticals Inc position peaked at $61K in Q3 2014.
0 funds tracked by Wall St. Rank held Alexza Pharmaceuticals Inc as of Q2 2016.

Based on Citadel Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.